Adial Pharmaceuticals（纳斯达克代码：ADIL）宣布与意大利制药企业Molteni Farmaceutici达成欧洲地区独家合作框架协议，共同推进酒精使用障碍治疗药物Ad04的研发与商业化。根据协议条款，若双方后续签署正式合作协议，Adial有望获得近6000万美元的潜在特许权使用费及里程碑款项。
该合作框架为Ad04在欧洲市场的临床开发、监管审批及商业化铺设了道路。作为一款针对特定基因型酒精使用障碍患者的创新疗法，Ad04此前已在临床研究中展现出降低复发率的潜力。此次合作将结合Molteni在欧洲市场的深厚渠道资源与Adial的专有技术，加速该疗法惠及目标患者群体。
业内人士指出，此类跨国合作不仅为生物科技公司提供了关键的资金与资源支持，亦凸显了欧洲市场对创新成瘾治疗方案的迫切需求。若最终协议顺利落地，Adial可通过阶段性里程碑付款和未来销售分成持续获得收益，进一步巩固其在精神疾病治疗领域的战略布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.